RxSight, Inc. is a commercial-stage medical technology company that researches, develops, manufactures, and sells light adjustable intraocular lenses (LAL) for cataract surgery in the United States. Its RxSight system allows doctors to customize and enhance patients' visual acuity after cataract surgery. The system includes the RxSight Light Adjustable Lens, made of photosensitive material that changes shape in response to specific ultraviolet patterns, and the RxSight light delivery device, an office-based device that delivers UV light in a programmed pattern to modify the lens. Formerly known as Calhoun Vision, Inc., the company changed its name to RxSight, Inc. in February 2017. It was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
▼
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
▼
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
▲
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.
Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
▼
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
▼
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
▲
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.
News & notes movingRXST
United StatesIndia
Biotech & Genomic Medicine▲
Alcon and RxSight Enter Strategic Collaboration on Adjustable Intraocular Lenses
Alcon Inc. and RxSight, Inc. announced on July 6 a non-exclusive strategic collaboration to co-develop post-operatively adjustable pseudophakic intraocular lenses, pairing RxSight's light-adjustable technology with Alcon's global commercial footprint and surgical equipment portfolio. The partnership validates RxSight's technology while expanding Alcon's premium lens offerings. In Q1 2026, Alcon reported net sales of $2.7 billion, up 10% year-over-year, with core diluted earnings per share of $0.85 and a new $1.5 billion share repurchase program, while RxSight posted revenue of $30.9 million, down 18.5% year-over-year, and a net loss of $15.9 million, or $0.38 per share, while reiterating full-year revenue guidance of $120 million to $135 million. Alcon also opened its second training center in partnership with the Aravind Eye Care System in India on July 24. Hedge fund ownership of Alcon rose to 46 funds in Q1 2026 from 44 in Q4 2025, while RxSight remained at 33 funds.
Alcon Q2 2026 Sales Rise 7%, Raises EPS Outlook on Strong Equipment and IOL Demand
Alcon Inc reported 7% sales growth in the second quarter of 2026, driven by broad-based strength across its surgical and vision care franchises. Unity VCS equipment sales surged 25% year-over-year with higher-than-expected average selling prices, while Panoptix Pro IOL adoption exceeded expectations, representing roughly 90% of Panoptix implants. Core operating margin expanded 160 basis points to 20.6%, and the company raised its full-year constant-currency EPS growth outlook to 12% to 15%. However, implantables growth remained subdued at 1%, with IOLs up only 2% amid competitive launches and flat US cataract procedure volumes. Alcon also discontinued its Power Vision IOL program due to performance issues and announced a collaboration with RxSight for next-generation adjustable lenses.
RxSight Withdraws 2026 Guidance After Revenue Decline and Alcon Deal
RxSight has withdrawn its full-year 2026 financial guidance as it pivots strategy following a 19% year-over-year drop in product sales and a new collaboration with Alcon. Second-quarter total revenue reached $33.7 million, including $6.5 million from the Alcon partnership, while product sales excluding that collaboration fell to $27.2 million. Light Adjustable Lens unit volumes declined 9% to 24,917, and gross margin excluding Alcon revenue slipped to 71.2% from 74.9% a year earlier. The company reported a net loss of $12.1 million, or $0.29 per share, and ended the quarter with approximately $209 million in cash and short-term investments, plus a $60 million upfront payment from Alcon received after the quarter closed. President and CEO Aziz Mottiwala said the guidance withdrawal allows a thorough business assessment without prior constraints, with formal guidance expected to resume in early 2027.
RxSight grants inducement equity awards to new CEO Aziz Mottiwala
RxSight announced inducement stock options and restricted stock units for new President and CEO Aziz Mottiwala. The options cover 571,286 shares at $5.19 per share, vesting 25% after one year and monthly thereafter over four years. The RSUs cover 2,312,138 shares, vesting 20% after one year, 20% after two years, and 60% after three years. The awards were granted under the 2026 Inducement Equity Incentive Plan as material inducements for his employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
RXST · Capital · Neutral Grant of inducement equity awards to new CEO, which is a standard compensation event with no clear directional signal for the company's performance.
RxSight Fair Value Drops to $8.43 After Soft Q2 and Guidance Cut
RxSight's modelled fair value has been lowered from $9.93 to $8.43 following softer second-quarter trends and a guidance cut. Jefferies reduced its price target from $7.50 to $6.50 with a Hold rating, while BofA cut its target from $8 to $6.50 and maintained an Underperform rating after preliminary Q2 sales of $27 million missed the $32 million Street expectation and 2026 guidance was reduced by $13 million at the midpoint. The revised valuation also reflects a shift in assumed revenue growth from 5.22% to 8.76%, a lower expected net profit margin from 12.79% to 11.76%, a future P/E multiple moving from 26.74x to 22.78x, and a discount rate easing from 7.85% to 7.45%. Analysts noted competitive trialing, macro pressures, and utilization at a four-year low, though BofA highlighted that the new Alcon collaboration could expand RxSight's reach into light adjustable PCIOLs over the longer term.
RXST · Capital · Negative RxSight reported preliminary Q2 sales of $27M missing $32M consensus and cut 2026 guidance by $13M, leading to multiple analyst downgrades and fair value reduction.
ALC.SW · Demand · Positive BofA noted that the new Alcon collaboration could expand RxSight's reach into light adjustable PCIOLs, potentially benefiting Alcon's product portfolio.
RxSight names Aziz Mottiwala CEO and Ron Kurtz CMO, cuts standalone 2026 sales outlook
RxSight announced that Aziz Mottiwala will become President and CEO effective July 20, 2026, succeeding Ron Kurtz, who will continue as Chief Medical Officer. Mottiwala previously served as Chief Commercial Officer at Tarsus Pharmaceuticals and Opiant Pharmaceuticals, and spent over a decade at Allergan in senior eye care leadership roles. The company also provided preliminary second-quarter 2026 revenue of $32 to $34 million, including $5 to $7 million from a recent Alcon collaboration, compared with $33.6 million a year earlier. For the full year 2026, RxSight expects total revenue of $140 to $160 million, but standalone sales excluding Alcon-based revenue are projected at $110 to $120 million, down from prior guidance of $120 to $135 million. Cash and short-term investments stood at approximately $209 million as of June 30, 2026.
RxSight projects 2026 revenue of $140M to $160M, including $30M to $40M from Alcon collaboration
RxSight has revised its full-year 2026 revenue outlook to a range of $140 million to $160 million, which includes $30 million to $40 million from its newly announced strategic collaboration with Alcon. The company's standalone RxSight sales are now expected to be $110 million to $120 million, reflecting the continuation of headwinds experienced in the second quarter. Preliminary second-quarter total company revenue is approximately $32 million to $34 million, with $5 million to $7 million attributed to the Alcon agreement, while standalone sales of roughly $27 million fell 20% year-over-year. Management attributed the slowdown to widespread competitive trialing activity and pressured consumer sentiment, and it plans to accelerate U.S. sales force investments to reengage accounts. Full-year gross margin guidance was raised to 73% to 75% due to a favorable product mix, while operating expenses are still expected at the high end of $150 million to $160 million.
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Alcon and RxSight have entered a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses. The partnership combines RxSight's post-operative light-adjustable technology with Alcon's PCIOL optical designs to create a co-developed technology that enables surgeons to fine-tune visual outcomes after cataract surgery. Under the agreement, RxSight will receive a $60 million upfront payment and could earn up to an additional $140 million in development and regulatory milestone payments. Alcon will lead global commercialization, while RxSight will handle development and manufacturing and receive royalties on net sales.
USA